Bridge to Nowhere
Taking a closer look at the opening act of a glioblastoma diagnosis.
Depth-First
Latest posts
Clock Yourself
My struggle against fear of falling and the app that helped me.
Compassion & Choices
Progress toward the best bad option.
Round Two
Every glioblastoma surgery fails sooner or later. Mine was no exception.
Median
Thoughts on crossing a statistical milestone.
My Struggle for a Good Death
Choosing from a wide selection of bad options.
The Witness
A short story.
Opting out of Optune
A treatment with small benefit and notable costs leads to a tough call.
DCA and Me
The proof of the pudding is in the eating.
Crystal Gardens
A chance encounter leads to a new life.
The Geiger Counter
Senior year at Willamette University brings new opportunities.
Living with Glioblastoma
It's the end of the line for treatment.
Beating Swords into Ploughshares
A returning WWII veteran takes up an unlikely field of study.
Growing Pains
A chaotic childhood leads to education and opportunity.
Sowing Seeds on Rocky Soil
Tracing my physicist grandfather's origins to an unexpected place.
Grandpa, What Did You Do at the Atom Bomb Factory?
First in a series investigating what exactly my grandfather did at the Hanford Engineer works.
How I Bought and Estimated the Purity of Sodium Dichloroacetate
Trust, but verify. On second thought, just verify.
Beware Oncologists Bearing Hope
Why interpretations from this special breed of doctor should be considered carefully.
Dichloroacetate
Treating my terminal disease like a research problem and finding a lead.
Progression
The Standard of Care treatment fails.
The California End of Life Option Act
Time to face the elephant in the room.
Just Saying "No" to Adjuvant Temozolomide
Discovering that the medicine cabinet for my terminal disease was filled with fluff.
George
Coming to terms with a disease that can change who you are.
Chemoradiotherapy
Undergoing a chemical and radiological exorcism.
Temodar, MGMT Methylation, and the Endless Loop of Bad Glioblastoma Treatments
Understanding why half of patients will take a drug offering little to no benefit.